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Regulation of apoptosis by lethal cytokines in human mesothe- rity of the peritoneal membrane by lubricating the peri-
lial cells. toneal surface, providing a nonadhesive surface and
Background. Dysregulation of peritoneal cell death may contributing to peritoneal defense. Loss of mesothelialcontribute to the complications of peritoneal dialysis (PD).
cells is a feature of both acute peritonitis and long-termChronic peritoneal dialysis and acute peritonitis are both asso-
peritoneal dialysis (PD) [1]. The regulation of cell num-ciated with loss of mesothelial cells. In addition, acute peritoni-
tis is characterized by sudden changes in the number of perito- ber results from the balance between mitosis and cell
neal leukocytes. However, the factors regulating peritoneal cell death. When cell death exceeds mitosis, cell number
survival are poorly understood.
decreases (reviewed in [2]). Thus, an inappropriate rateMethods. Peritoneal effluent cells and mesothelial cells cul-
of cell death could contribute to mesothelial cell loss intured from peritoneal dialysis patients were studied. Reverse
transcriptase-polymerase chain reaction (RT-PCR) and flow PD. However, the factors that regulate mesothelial cell
cytometry were used to assess the expression of FasL and Fas death are poorly understood. Exogenous factors, such
mRNA and protein. Western blot was used to assess FasL and as poorly biocompatible PD solutions, and endogenoustumor necrosis factor (TNF)-related apoptosis inducing ligand
mediators, such as lethal cytokines, could both contrib-(TRAIL). RT-PCR was used to study TRAIL and TRAIL
ute to mesothelial cell death. Indeed, PD solutions de-receptor mRNA. Apoptosis was quantified by flow cytometry
of DNA content and confirmed by morphology. crease the vitality and induce apoptosis in cultured peri-
Results. Apoptotic cells, including apoptotic mesothelial cells, toneal mesothelial cells [3]. Lethal cytokines are among
were present in the peritoneal effluent of stable peritoneal
the endogenous mediators that cause cell death (re-dialysis patients and patients with bacterial peritonitis. The
viewed in [2, 4]). Lethal cytokines belong to the ex-lethal cytokines FasL and TRAIL were expressed by peritoneal
effluent cells, while cultured mesothelial cells expressed FasL, panding tumor necrosis factor (TNF) superfamily. TNF
Fas, and TRAIL receptors. Cultured mesothelial cells were (TNFSF2), Fas ligand (FasL/TNFSF6), and TNF-related
sensitive to FasL-induced apoptosis. IFN increased the cell apoptosis-inducing ligand (TRAIL/TNFSF10) are thesurface expression of Fas and the sensitivity of mesothelial
most well-characterized members of this superfamiliy.cells to FasL-induced apoptosis. In contrast to the effect of
FasL, TNF and TRAIL did not induce apoptosis in human TNF is present in the peritoneal cavity in stable PD
mesothelial cells from peritoneal dialysis patients. patients and increases during inflammation [5]. However,
Conclusion. Lethal cytokines, such as FasL, may contribute there is less information regarding the role of FasL andto peritoneal cell turnover and the loss of mesothelium in
TRAIL on peritoneal physiology.peritoneal dialysis. The role of other cytokines, such as TRAIL,
FasL induces apoptosis through the activation of theremains undefined. Approaches in limiting mesothelial cell in-
jury that interferes with apoptosis should be considered. cell membrane Fas receptor (CD95/TNFSFR6) (re-
viewed in [6]). FasL induces apoptosis most efficiently
when it is present in a membrane-bound, trimeric form.
A continuous layer of mesothelial cells covers the peri- Although initially considered to be a T lymphocyte–
toneal membrane. Mesothelial cells promote the integ- specific cytokine, subsequent studies have demonstrated
that a variety of cell types express FasL, including renal
tubular epithelial cells and endothelial cells [7, 8]. FasL-Key words: apoptosis, Fas, mesothelium, peritoneal dialysis, TNF,
TRAIL. expressing cells are frequently resistant to the lethal ac-
tion of FasL [7, 8]. The Fas receptor is present on theReceived for publication May 2, 2002
cell surface of a wide variety of cells. However, Fas-and in revised form December 27, 2002
Accepted for publication February 25, 2003 expressing cells are not always sensitive to Fas-induced
apoptosis. A variety of molecular mechanisms may 2003 by the International Society of Nephrology
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account for resistance to the lethal action of FasL [6]. Jime´nez Dı´az. Patients signed an informed consent form
for these studies.TRAIL can induce apoptosis through the activation
of TRAIL receptor-1 (TRAILR1/DR4/TNFRSF10A)
Mesothelial cell cultureor TRAILR2 (DR5/TNFRSF10B), while TRAILR3
After centrifugation of peritoneal effluents, cells were(DcR1/TNFRSF10C) is a decoy receptor that protects
resuspended in 5 mL culture medium, seeded into 25 cm2against TRAIL-induced apoptosis [4].
tissue culture flasks, and incubated at 37C in a humidi-Information on the participation of the FasL-Fas sys-
fied atmosphere with 5% CO2 [9]. The culture medium,tem in peritoneal physiology is scarce. We have now
RPMI 1640 (Biowhitaker, Verviers, Belgium), supple-addressed whether FasL is present in the peritoneal cav-
mented with 20% fetal bovine serum (FBS), 100 U/mLity in PD patients, and whether mesothelial cells derived
penicillin, 100 g/mL streptomycin, and 2% Biogro-2from PD patients are sensitive to the lethal action of
(containing insulin, transferrin, ethanolamine, and pu-FasL under basal and proinflammatory conditions.
trescine) (Reactiva, Madrid, Spain), was replaced every
4 days.
METHODS Mesothelial cells were characterized by their morphol-
ogy and by immunohistochemistry staining [9]. Mesothe-Patients
lial cells were identified by their positivity for cytokera-In order to study the kinetics of cell number and apo-
tin, and negative staining for CD45 and von Willebrand’sptosis during peritonitis, the first turbid effluent and sub-
factor [9].sequent nocturnal effluents were studied in 10 culture
positive peritonitis episodes from continuous ambulatory Studies of cell death
PD (CAPD) patients treated at our center. The microor-
Human mesothelial cells were cultured to subcon-ganisms were gram-positive bacteria in 7 episodes and
fluence in 12-well plates and rested in serum-free media.gram- negative germs in 3 episodes. All patients were
Then, human recombinant aggregated FasL (Alexis,dialyzed with glucose-containing, lactate-buffered, pH
La¨ufelfingen, Switzerland), human recombinant aggre-5.5 PD fluids. No patient was diabetic. Mean age was 66
gated TRAIL (Alexis), or TNF (Immunogenex, Los14 years, 5 females and 5 males. Causes of renal failure
Angeles, CA, USA) were added for 24 hours. The lethalincluded hypertensive kidney disease [3], ischemic ne-
cytokine concentration was based on prior experience
phropathy [2], glomerulonephritis [3], interstitial ne-
with other cell types [7, 10]. Apoptotic cell death was
phropathy [1], and renal hypoplasia [1]. Time on PD
quantified by flow cytometry of DNA content in perme-
ranged from 11 to 62 months. A peritoneal effluent sam- abilized, propidium iodide–stained cells, as described in
ple was divided into two portions. In one portion leuko- detail in previous publications [7, 10]. Briefly, cells
cytes were quantified by Coulter (Beckman Coulter, Ful- attached to the plate were detached with trypsin/ethyl-
lerton, CA, USA). In the other portion, apoptosis was enediaminetetraacetic acid (EDTA), collected, and mixed
studied by flow cytometry of cell DNA content. Samples with detached cells present in the supernatant. Cells were
were also obtained within the first 48 hours of peritonitis spun and resuspended in 100g/mL propidium iodide, 10
to study lethal cytokine and death receptor expression. g/mL RNAse A, 0.05% NP-40 in phosphate-buffered
For these experiments, 5 stable patients in whom samples saline (PBS), incubated at 4C for 1 hour, and analyzed
were available after a period of more then 2 months on the FACScan using Lysis II software (Becton Dickin-
without peritonitis were the control group. They were son, Franklin Lakes, NJ, USA). We must emphasize that,
nondiabetic CAPD patients with a mean age of 63  22 as cells were permeabilized, this method is not based on
years, 2 females, 3 males. Causes of renal failure included the ability of living cells to exclude propidium iodide. The
hypertensive kidney disease (1), ischemic nephropathy percentage of hypodiploid cells, as assessed by decreased
(1), glomerulonephritis (2), and polycystic kidney disease DNA staining (A0), comprising apoptotic cells with frag-
(1). Time on PD ranged from 2 to 62 months. mented nuclei, was counted [7, 10]. In some experiments
In order to establish mesothelial cell cultures, noctur- cells were incubated for 24 hours with human TNF
nal peritoneal effluents from 6 stable CAPD patients or IFN (Immunogenex, Tragen Pharmaceuticals, San
were processed as previously described [9]. All patients Diego, CA, USA) prior to the addition of FasL [7]. FasL
were dialyzed with glucose-containing, lactate-buffered, aggregation is required to simulate the active form of
pH 5.5 PD fluids. No patient was diabetic. Mean age was FasL, membrane-bound FasL. For this purpose, FasL is
52  16 years, 5 females, 1 male. Causes of renal failure incubated in the presence of an enhancer, a nonlethal
included glomerulonephritis (2), polycystic kidney dis- antibody, prior to its use [7]. For morphologic assessment
ease (2), renal hypoplasia (1), and renal tuberculosis (1). of apoptosis, cells were cultured in chamber slides (Lab-
Time on PD ranged from 2 to 12 months. The study was tek, Nunc, Inc., Naperville, IL, USA), fixed with metha-
nol:acetone (1:1), and stained with propidium iodide inapproved by the clinical ethics committee of Fundacio´n
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membranes. The membranes were blocked with 5% skimthe presence of RNAse A [7]. The experiments were
milk in PBS/0.5% v/v Tween 20 for 1 hour, washed withrepeated with cells cultured from 5 different patients.
PBS/Tween, and incubated with rabbit polyclonal anti-Apoptosis was also assessed by flow cytometry in sam-
FasL antibodies (0.5 g/mL) or mouse monoclonal anti-ples from peritoneal effluents.
human TRAIL antibodies (1.5 g/mL; Pharmingen) in
Flow cytometry analysis of FasL and Fas expression 5% milk PBS/Tween for 18 hours at 4C. The blots were
washed with PBS/Tween and subsequently incubatedTo study FasL expression, 5 105 cells were fixed in
with horseradish peroxidase-conjugated anti-rabbit IgG2% glutaraldehyde/PBS, washed in PBS, and permeabil-
(1:2500; Amersham Pharmacia Biotech, Buckingham-ized in 0.1% triton X-100, 2% bovine serum albumin
shire, UK) or anti-mouse IgG (1:2500; Amersham). After(BSA), 1% goat serum, in PBS for 30 minutes at room
washing with PBS/Tween, the blots were developed withtemperature [11]. The cells were then incubated with
the chemiluminescence method (ECL) following the1g/mL rabbit polyclonal anti-FasL (aminoacids 2-19 in
manufacturer’s instructions (Amersham). FasL-trans-FasL) (Santa Cruz Biotechnology, Santa Cruz, CA,
fected 293 cell lysates (a gift from J. Tschopp) wereUSA) in 0.1% Triton X-100, 0.2% BSA, in PBS for 60
diluted 10-fold and used as positive controls. As a nega-minutes, followed by incubation with 1:100 fluoroscein
tive control the antibodies were preincubated with aisothiocyanate (FITC) goat anti-rabbit IgG for 60 min-
tenfold excess of the immunogenic peptide prior to West-utes [11]. Control samples were stained with preimmune
ern blotting. Peritonitis samples were obtained withinrabbit IgG. Cells were analyzed on a cytofluorograph
and debris were excluded from analysis by selective gat- the first 48 hours of evolution of peritoneal inflammation.
ing based on anterior and right angle scatter. At least
RT-PCR10,000 events were collected for each sample, and data
were displayed on a logarithmic scale of increasing fluo- Total RNA was isolated from the cell pellet of perito-
rescence intensity [11]. neal effluents or from cultured mesothelial cells using
To study cell surface Fas expression, mesothelial cells the Trizol Reagent (Life Technologies, Grand Island,
from 6 patients were detached with 2 m EDTA follow- NY, USA). FasL, Fas, TRAIL, and TRAIL receptor
ing culture in the presence of control medium or cyto- mRNA were detected by reverse transcriptase-polymer-
kines for 24 to 48 hours. Cells (5  105) were incubated ase chain reaction (RT-PCR). RT-PCR was carried out
for 30 minutes at 4C with 20 g/mL anti-Fas CH-11 as previously described [7]. Given the big differences in
antibody (Upstate Biotechnology, Lake Placid, NY, the amount of RNA obtained from control PD effluents
USA) or 20 g/mL control IgM [12] followed by a 30 and peritonitis effluents, direct comparisons were not
minute, 4C incubation with 1:100 FITC-secondary anti- made and processing of the sample differed. From perito-
body (Pharmingen, San Diego, CA, USA). Mean cell nitis effluents, 50 mL of the sample were spun and RNA
fluorescence was calculated using Lysis II software. Peri-
isolated from the pellet and quantified. One hundred ngtoneal effluent samples were stained in the same manner.
of RNA were used in the RT-PCR. From control efflu-
ents, 500 mL were processed and RT-PCR was carriedImmunofluorescence
out directly, without previous quantitation of RNA. TheIn 5 samples from 3 patients with peritonitis (3 on day
primers (Genosys, London, UK) used were obtained1, 2 on day 7), cells were fixed with methanol-acetone
from the genebank sequences [13–18]: FasL (Accesionand costained with propidium iodide and anti-cyto-
number U11821) sense: 541-TCTGGAATGGGAAGkeratin 8/18 antibodies for assessment of the presence
ACAC, FasL antisense: 828-TCAGCACTGGTAAGAof apoptotic mesothelial cells. In addition, cells were
TTG; Fas (M67454) sense: 419-CAATGGGGATGAAstained with anti-Fas or anti-FasL antibodies with or
CCAGACTGC, Fas antisense: 742-GGCAAAAGAAGwithout costaining with propidium iodide and observed
AAGACAAAGCC; TRAIL (U37518) sense: 136-GTGand photographed under a fluorescence microscope.
CTGATCGTGATCTTC, TRAIL antisense: 561-CCA
CTCCTTGATGATTCC; TRAIL R1 (U90875) sense:Western blot
416-CAGAACGTCCTGGAGCCTGTA AC, TRAIL R1Western blot was performed according to previously
antisense: 714-ATGTCCATTGCCTGATTCTTTGTG;described methods [7, 10]. Cell samples were homoge-
TRAIL R2 (AF020501) sense: 434-GGGAAGAAGATTnized in lysis buffer (50 m Tris-HCl, 150 m NaCl, 2m
CTCCTGAGATGTG, TRAIL R2 antisense: 725-ACATEDTA, 2m ethyleneglycol tetraacetate (EGTA), 0.2%
TGTCCTCAGCCCCA GGTCG; TRAIL R3 (AF020502)triton X-100, 0.3% NP-40, 0.1 m phenylmethylsulfonyl
sense: 551-GGGATGATATCCAGTGTGTTGAAG,fluoride (PMSF) and 1g/mL pepstatin A, then 30 g
TRAIL R3 antisense: 857-ACGATGGTGCATGAGAprotein were loaded and separated by 12% sodium dodecyl
GGTAATGAG. The size of the PCR products, anneal-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
ing temperatures, and the number of cycles are as fol-under reducing conditions. After electrophoresis, sam-
ples were transferred to polyvinylidine difluoride (PVDF) lows: FasL, 287 bp, 62C, 35; Fas, 324 bp, 62C, 25;
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Fig. 1. Cell number and apoptosis in peritoneal effluent during peritonitis. (A ) Detail of an apoptotic cell in the peritoneal effluent of a patient
with peritonitis. Note the condensed and fragmented nucleus. (H&E, magnification500). (B ) Shrunken apoptotic mesothelial cell in the peritoneal
effluent. Note the cytokeratin 8/18 positivity in the cytoplasm (green) and the pyknotic, bright and fragmented nucleus (immunofluorescence and
propidium iodide staining of a fixed sample, magnification 100). (C ) Nonapoptotic mesothelial cells in the effluent, stained by the same technique
as (B). Note the oval, pale nuclei (magnification, 100). (D ) Sequential changes in cell number in the course of peritonitis. Mean  SD of 10
episodes of peritonitis. *P  0.05 vs. other time points. (E ) Sequential changes in the percentage of apoptotic cells, measured as hypodiploid cells.
Mean  SD of 10 episodes of peritonitis. *P  0.05 vs. other time points.
TRAIL, 430 bp, 54C, 40; TRAIL R1, 298 bp, 59C, 35; in the effluent (Fig. 1). From 0.5 to 5% of the effluent
cells were considered mesothelial, based on cytokeratinTRAIL R2, 291 and 391 bp, 62C, 40; TRAIL R3, 306 bp,
staining. Around 50% of these were apoptotic on days60C, 35. PCR for glyceraldehydes-3-phosphate dehy-
one or seven. Furthermore, we have studied the kineticsdrogenase (GAPDH) was run in parallel. Samples were
of cell number and the apoptosis rate in the peritonealonly considered negative for cytokine or receptor mRNA
effluent during peritonitis. The number of leukocytesexpression if GAPDH mRNA was detected.
was maximal in the effluent of the first cloudy exchange
or in the exchanges obtained during the first 48 hoursStatistics
of peritonitis. Then there was a rapid fall in total cellData are expressed as mean  SD. Significance at the
number over the next days (Fig. 1). By contrast, in theP  0.05 level was assessed by nonparametric Mann-
first exchanges, a low apoptosis rate was observed (Fig.Whitney test for two groups of data and Kruskal-Wallis
1). The apoptosis rate increased in the next few days,for three or more groups.
coinciding with the fall in total cell number. These data
suggest that apoptosis is a mechanism to clear peritoneal
leukocytes, but there is no information about the factorsRESULTS
responsible for the death of leukocytes. In addition, apo-
Apoptosis of peritoneal cells during peritonitis ptosis could contribute to the demesothelization that has
There is little information on the participation of apo- been described during peritonitis.
ptosis in PD complications. We have observed the pres-
Lethal cytokine expression by peritoneal cellsence of apoptotic cells in peritoneal effluents of patients
with peritonitis (Fig. 1). Most apoptotic cells were leuko- As a first step toward elucidating the factors responsi-
ble for peritoneal cell apoptosis, we looked for the ex-cytes. However, apoptotic mesothelial cells were present
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Fig. 2. Lethal cytokine expression by perito-
neal effluent leukocytes and cultured meso-
thelial cells. (A ) FasL mRNA expression: re-
verse transcriptase-polymerase chain reaction
(RT-PCR) of peritoneal effluent leukocytes in
a stable patient. (B ) FasL cytokine expression:
flow cytometry diagram from peritoneal ef-
fluent leukocytes during peritonitis. (C ) FasL
cytokine expression during peritonitis. Both
neutrophil leukocytes (arrow) and mesothelial
cells (arrowhead) were stained by anti-FasL
antibodies (immunofluorescence, original mag-
nification 50). (D) FasL cytokine expression:
Western blot of peritoneal effluent leukocytes.
(E ) FasL mRNA expression: RT-PCR of cul-
tured human mesothelial cells. (F ) FasL cyto-
kine expression: Western blot of cultured
human mesothelial cells. (G ) TRAIL mRNA
expression: RT-PCR of peritoneal effluent
leukocytes in a stable patient. (H) TRAIL cyto-
kine expression: Western blot of peritoneal
effluent leukocytes. The figures are represen-
tative of results obtained with peritoneal ef-
fluent cells from five (control, noninfected,
stable patients) and five (FasL), or 10 (TRAIL)
peritonitis patients. MWM is molecular weight
marker. [DNA MWM VI Roche in (A), Pro-
mega pGEM in (E) and (G)].
pression of the lethal cytokines FasL and TRAIL in ever, this band could not be detected in stable PD pa-
tients (Fig. 2D). We then investigated FasL expressionperitoneal effluent cells. By RT-PCR, peritoneal effluent
cells were shown to express FasL mRNA both in stable in cultured mesothelial cells from patients on PD. We
observed that mesothelial cells express FasL mRNApatients (5/5) and during peritonitis (5/5) (Fig. 2A). FasL
mRNA was more difficult to detect in stable patients. (Fig. 2E) and protein with a size consistent with mem-
brane-bound FasL (Fig. 2F). These results show that FasLIndeed, up to 500 mL of fluid had to be processed to
is synthesized locally in the peritoneum and could haveconsistently detect the message in the cell pellet, while
actions over infiltrating leukocytes and mesothelial cells.a portion of the RNA obtained from less than 50 mL of
We also demonstrated the presence of TRAIL mRNAperitonitis effluent was enough to detect FasL mRNA.
and protein in peritoneal effluent cells from 3 out of 5By flow cytometry, we observed that peritoneal effluent
stable PD patients and 10 out of 10 patients with peritoni-cells, most of them leukocytes, express the cytokine FasL
tis (Fig. 2 G and H).during peritonitis (Fig. 2B). Immunofluorescence mi-
croscopy showed that both mesothelial cells and leuko-
Peritoneal leukocytes and human mesothelial cellscytes express FasL in the inflamed peritoneum (Fig. 2C).
express death receptorsBy Western blot we could demonstrate the presence
of a 40 kD protein reacting with anti-FasL antibodies, Peritoneal effluent cells from both stable and peritoni-
tis patients express Fas mRNA (Fig. 3A). In addition, byconsistent with membrane-bound FasL, in the effluent
cell pellet of the 5 patients with peritonitis tested; how- flow cytometry, we could show that peritonitis leukocytes
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Fig. 3. Peritoneal effluent cells express death
receptors. (A ) mRNA expression of Fas dur-
ing peritonitis in peritoneal effluent cells [re-
verse transcriptase-polymerase chain reaction
(RT-PCR)]. (B ) Cell surface membrane Fas
expression in peritoneal effluent leukocytes
during peritonitis (flow cytometry). Cells were
stained with either nonimmune IgM or anti-
Fas IgM. The figures are representative of re-
sults obtained with cells from five stable pa-
tients and five peritonitis patients. (C ) Both
leukocytes (arrow) and mesothelial cells (ar-
rowhead) were stained by anti-Fas antibodies
(immunofluorescence, original magnification
50). (D ) mRNA expression of Fas in cul-
tured human mesothelial cells from peritoneal
dialysis (PD) patients (RT-PCR). (E ) Cell
surface Fas expression in cultured human
mesothelial cells (flow cytometry). Cells were
stained with either nonimmune IgM or anti-
Fas IgM. (F ) mRNA expression of tumor ne-
crosis factor (TNF)-related apoptosis inducing
ligand (TRAIL) receptors in cultured human
mesothelial cells from PD patients (RT-PCR).
TRAILR2 has two known transcripts corre-
sponding to the two bands observed. MWM
is molecular weight marker.
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Fig. 4. Regulation of mesothelial cell Fas by
cytokines. (A ) Cell surface Fas expression in
cultured human mesothelial cells (flow cytom-
etry) in the presence of IFN- (300 U/mL)
and/or TNF (5000 U/mL) for 24 hours. Thin
line, control IgG; thick line, anti-Fas. (B) Quan-
tification of mean cell fluorescence changes in
Fas expression (flow cytometry) induced by
cytokines in human mesothelial cells. *P 
0.05; **P 0.02 vs. control. Mean  SD of du-
plicate experiments repeated with cells from
six different patients.
express the Fas receptor on the cell surface (Fig. 3B). tive lymphoid cells, as previously shown by our group
[7]. IFN-, an inflammatory cytokine released duringMicroscopy demonstrated that Fas was expressed both
peritonitis [19], increased FasL lethality. Although TNFby leukocytes and by mesothelial cells from the PD ef-
is, by itself, a potentially lethal cytokine [10], we did notfluents (Fig. 3C).
observe a lethal effect in mesothelial cells (Fig. 5A). ItCultured mesothelial cells from PD patients express
is interesting to note that high concentrations of TNFthe mRNA encoding Fas (Fig. 3D). By flow cytometry
increased the sensitivity of cells to FasL induced-apopto-the Fas receptor was detected on the cell surface of
sis, despite the fact that they did not significantly modu-most mesothelial cells (Fig. 3E). Mesothelial cells also
late Fas expression. By contrast, the other lethal cytokineexpressed mRNA for TRAILR1, TRAILR2 (both
expressed in peritoneal effluents, TRAIL, does not in-known transcripts) [18], and TRAILR3 (Fig. 3F). Incu-
duce mesothelial cell apoptosis under basal conditionsbation with 300 U/mL IFN- increased Fas expression,
or in cells stimulated with a high concentration of TNFas assessed by mean cell fluorescence, by 40% at 24 hours
(Fig. 5C).(Fig. 4). By contrast, we did not observe a significant
effect of TNF 500 to 5000 U/mL for 24h on Fas expres-
sion (Fig. 4). DISCUSSION
Chronic mesothelial cell loss is a significant problemFasL induces apoptosis of human mesothelial cells
in PD [1]. Apoptotic cell death may contribute to pro-
We next dealt with the functional repercussion on gressive mesothelial cell depletion [20, 21]. An inade-
mesothelium of the presence of lethal cytokines in the quate amount of mesothelial cell survival factors, the
peritoneum. In particular, we explored whether FasL presence of lethal cytokines, or the presence of cell stress
could be one of the factors that is responsible for the factors such as poorly biocompatible PD fluid could theo-
loss of mesothelium that is associated with peritoneal retically contribute to mesothelial cell loss. We have now
inflammation. We showed that cultured mesothelial cells demonstrated that the lethal, membrane-bound form of
are relatively resistant to FasL, although high concentra- FasL is present in the peritoneal cavity and that mesothe-
tions induce apoptosis in a dose-dependent fashion (Fig. lial cells are primed by proinflammatory cytokines to
5 A and B). Increasing the incubation time to 48 and 72 undergo apoptosis upon exposure to a trimeric form of
hours did not result in further apoptosis induced by 10 FasL that is similar to that found bound to membranes.
ng/mL FasL, even in the presence of cytokines (not A significant number of apoptotic cells was found
shown). Mesothelial cells were resistant to 1 ng/mL FasL among peritoneal effluent cells in the course of peritoni-
even in the presence of cytokines (not shown). This low tis. Initially the proportion of apoptotic cells was low,
but given the total amount of cells, the absolute numberconcentration of FasL readily induces apoptosis in sensi-
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Fig. 5. Lethal cytokines and apoptosis in human mesothelial cells. (A ) Quantification of apoptosis by flow cytometry. Cells were incubated with
control medium or with TNF (500 to 5000 U/mL) or IFN- (300 U/mL) for 24 hours; FasL was then added and the incubation continued for 24
additional hours. *P  0.01 vs. control; **P  0.05 vs. 100 ng /mL FasL control in the absence of cytokine prestimulation. Mean  SD of duplicate
experiments repeated with cells from five different patients. (B ) Flow cytometry analysis of apoptosis in FasL (100 ng/mL)-treated, IFN- (300
U/mL)-stimulated cells. The D bar encompasses hypodiploid, apoptotic cells. Inset: morphologic evidence of apoptosis (condensed, shrunken,
bright nuclei) in FasL (100 ng/mL)-treated, IFN- (300 U/mL)-stimulated cells stained with propidium iodide following permeabilization of the
cell membrane (arrows). (C ) Quantification of apoptosis by flow cytometry. Cells were incubated with control medium or with TNF (5000 U/mL)
for 24 hours and then tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) (100 ng/mL) was added and the incubation continued
for 24 additional hours. Experiments were repeated with cells from five different patients.
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of apoptotic cells was high. During the evolution of peri- the complexities of the regulation of Fas-induced apo-
ptosis, this cannot be predicted [6]. As an example, IFNtonitis, the proportion of apoptotic cells progressively
increased. Our observation proves the point that signifi- increases Fas expression in endothelium, as it does in
mesothelium, but it does not facilitate FasL apoptosis incant apoptosis occurs in the peritoneal cavity during peri-
tonitis. Similar observations have been made in an ani- endothelial cells [8]. By contrast, oxidized-LDL de-
creases the levels of the intracellular protective proteinmal model of PD peritonitis [22]. Apoptosis could
contribute both to the clearance of leukocytes and to Fas-associated death domain-like interleukin-1 beta-con-
verting enzyme-like inhibitory protein (FLIP) and sensi-mesothelial cell depletion. Indeed, apoptotic mesothelial
cells were present in the peritoneal effluent. However, tizes endothelium to autocrine FasL–mediated apoptosis
[28]. In our own study, high-dose TNF increased FasLmost apoptotic cells under these circumstances are leu-
kocytes, as observed in animal models [22]. This is not lethality, although no significant changes in Fas expres-
sion were detected. TNF has other proapoptotic activi-surprising, as most cells in the peritoneal effluent are
leukocytes. Leukocyte apoptosis contributes to their ties that may sensitize cells to Fas-induced apoptosis.
For example, it lowers BclxL expression in renal cellsclearance and to resolution of the inflammatory process
[23]. However, in vitro data suggest that an accelerated [10]. In this regard, mesothelial cells express cell mem-
brane Fas receptors both in the peritoneal effluent and inleukocyte apoptotic rate induced by PD solutions may
contribute to the impaired peritoneal defense in PD [24]. culture, so the molecular mechanism behind the relative
resistance of mesothelial cells to the lethal action ofzVAD, a pancaspase inhibitor, increased survival and
antibacterial activity in neutrophils exposed to PD solu- FasL are not known, and should be dealt with in further
studies. Expression of soluble Fas, soluble FasL, FLIP,tions [23]. Indeed, inhibition of apoptosis by broad-spec-
trum caspase inhibitors has been successfully used in the SODD, BclxL, or activation of NFB is a potential candi-
date [4]. Mesothelial cells were resistant to apoptosisexperimental setting to accelerate recovery from perito-
nitis in the presence of PD solutions [22]. Apoptotic cells induction by high concentrations of aggregated TRAIL.
In this, mesothelial cells differ from endothelial cells [29].keep their apoptotic morphology for only a few hours
and then are readily cleared by adjacent cells. Thus, the The role of TRAIL in peritoneal physiology remains to
be defined. Potential actions of TRAIL besides inducingfact that apoptotic mesothelial cells are identified in the
effluent means that a significant degree of mesothelial apoptosis include activation of NFB [30].
The physiologic role of FasL expression by mesothelialcell apoptosis is taking place.
TNF, FasL, and TRAIL are the main lethal members cells remains unknown and further studies are needed
to delineate the role of mesothelial cell–derived FasL inof the TNF superfamily of cytokines [4]. TNF and FasL
are upregulated during inflammation at different sites, peritoneal physiology. FasL is usually stored in intracel-
lular membranes within the cytoplasm and can inducesuch as the kidneys [6, 7, 25]. TNFwas previously shown
to be expressed during PD and upregulated in peritonitis apoptosis upon exposure on the cell surface or upon
release of FasL-laden microvesicles [31]. We may specu-[5]. The physiologic role of TRAIL is less well under-
stood. However, it is known to be upregulated by bacte- late that FasL in mesothelium can behave as endothelial
cell FasL. Endothelial cell FasL plays a role in limitingrial pathogens [26]. Although our study was not designed
to precisely quantitate the kinetics of cytokine expres- the transendothelial traffic of leukocytes [32]. In this
regard, FasL regulates leukocyte survival [33]. Alterna-sion during peritonitis, we have now observed that both
FasL and TRAIL are expressed in the peritoneum during tively, the release of soluble FasL may protect mesothe-
lial cells from membrane-bound FasL, as is the case forPD and we have explored the potential contribution of
lethal cytokines to mesothelial cell death. Among them, hypoxic endothelium [34].
Our data indicate that different potentially lethal cyto-FasL appears to be the most lethal for mesothelial cells
from PD patients. As expected by their constitutive ex- kines are present in the peritoneum during PD. The role
of some of them, such as TRAIL, is not yet defined.pression of FasL, mesothelial cells are resistant to low
concentrations of FasL, even in the presence of proin- Others, such as FasL, may contribute to mesothelial cell
depletion in PD patients, especially during peritonitis.flammatory cytokines. However, high concentrations of
FasL induce mesothelial cell death, especially in the pres- However, FasL may have additional roles. Based on
recent data on the beneficial effect of caspase inhibitorsence of cytokines released during peritoneal inflamma-
tion, such as IFN or TNF [5, 19]. Such a high concen- in the evolution of experimental peritonitis [21, 35], and
on the fact that broad-spectrum caspase inhibitors alsotration of cell membrane–bound FasL is expected to
occur during peritonitis as the number of peritoneal leu- inhibit FasL-mediated apoptosis in vivo [36], the acute,
short-term use of caspase inhibitors should be consideredkocytes bearing FasL increases by 70fold. It is possible
that other stimuli that increase Fas expression in human in experimental PD with the additional goal of increasing
the peritoneal defense and preventing mesothelial cellmesothelium, such as PD solutions [27], also increase
the sensitivity to apoptotic cell death. However, given injury.
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